Answers are grounded in this paper and cite their sources.
The prognosis for children and adolescents with rhabdomyosarcoma (RMS) has improved with refinements in multi-modal therapy. Since 1972, the Intergroup Rhabdomyosarcoma Study Group (now the Children's Oncology Group Soft-Tissue Sarcoma Committee) has conducted serial studies for RMS. This review describes the IRSG and COG experience with RMS, presents the current risk stratification definitions, and provides rationale for the current generation of COG RMS studies.
No takes yet. Share an insight, caveat, or question.
Malempati et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: